Navigation Links
Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Date:5/7/2009

PHILADELPHIA, Pennysylvania, May 7 /PRNewswire-FirstCall/ -- Elsevier, one of the world's leading publishers of scientific, technical, and medical (STM) information products and services, announced today that Michael Hansen, CEO of Elsevier's Health Sciences Division, issued the following statement in light of recent allegations of improper Australia based sponsored journal publication practices between 2000 and 2005:

"Elsevier prides itself on operating its business in the most ethical, honest and transparent manner possible. We have been stewards of the scientific record for more than 125 years and we take our role in advancing medical and scientific research seriously.

It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took place.

We are currently conducting an internal review but believe this was an isolated practice from a past period in time. It does not reflect the way we operate today. The individuals involved in the project have long since left the company. I have affirmed our business practices as they relate to what defines a journal and the proper use of disclosure language with our employees to ensure this does not happen again.

We will continue to partner with all scientists and clinical investigators, including those in the pharmaceutical industry, to help communicate the findings of high-quality, peer-reviewed medical research. We have strict disclosure rules in place so that readers are aware of any financial interests behind a specific article or journal, or when entire compilation products are created for pharmaceutical marketing purposes.

I understand this issue has troubled our communit
'/>"/>

SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ... Company,s lead antibody, HuMab 5B1, will be garnering major ... the upcoming World Molecular Imaging Congress (WMIC) being held ... Researchers from the Department of Radiology at Memorial Sloan ... use of MabVax,s lead antibody as a PET imaging ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015 FLX ... and development of novel cancer immunotherapies, announced today that ... as Chief Executive Officer and William Ho , ... Ho join an experienced management team led by veterans ... Fridman , Ph.D., Chief Scientific Officer; Jay Powers ...
(Date:8/31/2015)... , ... August 31, 2015 , ... There’s a new ... Minerva is the first commercially available new FDA approved system in the last 14 ... of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... ... Parkinson,s disease patients. Daniel Neal from Palm Springs, CA, gains the ability and confidence to ... ... portable device improves walking for Parkinson,s disease patients. Daniel Neal from Palm Springs, CA, gains ...
... LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies Corp. (Nasdaq: ... class collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, ... Industry" Conference on Wednesday, September 16, 2009, at 9:00 am ... New York, NY. , , A live ...
... ... to demonstrate the power of nanotechnology based regenerative medicines. , ... (PRWEB) September 11, 2009 -- Long-time financier ... to rejuvenate living animals with advanced nanotechnologies developed by his labs. The goal of ...
Cached Biology Technology:New Superman Glasses for Parkinson's Disease Improve Walking and Quality of Life 2Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... years ago, the understory of late Mesozoic forests was dominated ... Today, only one genus from this group, Equisetum ... a prime candidate for being the oldest extant genus of ... the evolutionary beginnings of the genus Equisetum . Molecular ...
... The ability to use nanoparticles to deliver payloads of ... a fundamental change in chemotherapy treatment. But scientists are ... of this technology. Although developing nanoparticles ... while sparing normal, healthy tissues is still the ...
... from the Howard Hughes Medical Institute (HHMI)will be used ... to enable thousands of college and university science faculty ... biology education. The $3 million grant will expand ... Biology from a single location at the University of ...
Cached Biology News:Newly discovered plant fossil reveals more than age 2Newly discovered plant fossil reveals more than age 3Newly discovered plant fossil reveals more than age 4Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say 2HHMI helps summer institute expand to regional sites 2HHMI helps summer institute expand to regional sites 3HHMI helps summer institute expand to regional sites 4
Contains L-glutamine...
... The PhosphatidylEthanolamine-Binding Protein (PEBP) does ... serine protease inhibitors. PEBP is ... spleen, testis, ovary, muscle, and stomach. ... involved in is exerting inhibitory activity ...
...
Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
Biology Products: